Diego Ruiz Dasilva, MD, FAAD: Achievement of Optimal Treatment Targets with Oral JAK Inhibition in Elderly Patients with Atopic Dermatitis

Dr. Dasilva discusses positive results from a recent study published in the Journal of Clinical and Aesthetic Dermatology that assessed the safety and efficacy of JAK inhibitors in a group of elderly patients. Click here to read the full article.

Reference:

  1. Dasilva DR, Desir N, Encarnacion IN, et al. Achievement of Optimal Treatment Targets with Oral Janus Kinase Inhibition in Elderly Patients with Atopic Dermatitis: A Real-world, Multicenter, Retrospective Study. J Clin Aesthet Dermatol. 2025;18(2):25–29.

MORE EXPERT PERSPECTIVES IN ATOPIC DERMATITIS

Andrew Mastro discusses various challenges of treating AD in the head-and-neck area, emphasizing the importance in choosing a treatment armed with rapidity, power, and a

Dr. Issa discusses a real-world study¹ that demonstrated a reduced need for biologic treatments, among other AD treatments, in patients treated with topical ruxolitinib cream,

Lisa Swanson, MD, JCAD’s Section Editor of Pediatric Dermatology, shares her thoughts on new research evaluating maximum-use conditions for topical ruxolitinib cream in pediatric patients

Dr. Cameron discusses promising results in a treatment that combined upadacitinib and topical corticosteroids. Reference:

Looking to the future of AD treatment, Dr. Song discusses the unmet need of predicting treatment responses in patients with atopic dermatitis, with the aim

Melodie Young discusses managing treatment for younger children with atopic dermatitis, emphasizing the importance of focusing on potential and probable side effects with their caregivers.

Dr. Song discusses the latest safety data on topical and oral JAK inhibitors for patients with atopic dermatitis.

Melodie Young discusses the logistics of gaining access to newer medications through speciality pharmacies for patients with atopic dermatitis.
Dr. Del Rosso discusses the current topical treatments available for patients with atopic dermatitis that have shown consistent efficacy with limited adverse events.
Dr. Chovatiya discusses the effectiveness of providing a moisturizer in combination with a topical or systemic therapy to achieve clear skin regardless of disease severity.
Andrea Nguyen, PA-C, MS, discusses how the internet and social media has contributed to more in-depth discussion with her patients regarding treatment for atopic dermatitis.
Dr. Chovatiya reviews some of the essentials to look for in moisturizers such as a treatment that is semipermeable and has natural moisturizing factors.
TJ Chao breaks down the black box warnings for ruxolitinib cream 1.5% and discusses the importance in communicating the specifics of these warnings to patients.
Dr. Chovatiya discusses the benefits of a moisturization routine as a complement to all currently available therapies for patients with atopic dermatitis.
Mr. Chao discusses the reliability of ruxolitinib cream 1.5% in treating patients with atopic dermatitis. He emphasized how well it is tolerated by patients, as
Dr. Matthew Zirwas reviews atopic dermatitis treatments that have been essential in providing immediate improvement in itch leading to a sense of control in his
Dr. Silverberg discusses how to safely counsel patients when deciding between topical versus oral JAK inhibitors for the treatment of atopic dermatitis.
Dr. Lio discusses the effects of topical ruxolitinib in his patients with atopic dermatitis, and how he incorporates this treatment into his practice.
Dr. Friedman discusses how to evaluate patients with atopic dermatitis to match them with their best treatment as well as the importance of keeping a
Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses
Raj Chovatiya, MD, PhD, Director of the Center for Eczema and Itch at the Department of Dermatology at Northwestern University Feinberg School of Medicine, discusses
Peter Lio, MD, of Medical Dermatology Associates of Chicago in Chicago, Illinois, discusses recent innovations in atopic dermatitis therapies with regard to JAK inhibitors. Dr.